

Imugene to present at the 2016 Biotech Showcase

Melbourne, Australia, 22 December 2015: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, announces that the Company will present at the 2016 Biotech Showcase in San Francisco, to be held 11-13 January. Leslie Chong, Chief Operating Officer of Imugene, will present an overview of Imugene and its groundbreaking HER-Vaxx cancer immunotherapy, as well as discuss the company's exciting prospects for 2016 as HER-Vaxx enters its key Phase 1b/2 clinical study in gastric cancer.

Event: Eighth Annual Biotech Showcase

Date: Monday, January 11 2016

Time: 4:00 p.m. (PST)

Location: Mission II room, 4th Floor, Parc 55 San Francisco

A copy of Ms Chong's presentation will be made available on ASX and the company's web site prior to the presentation.

About Imugene and HER-Vaxx

Imugene (ASX: IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Imugene's lead product is HER-Vaxx, a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a known and validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer. For further information, please visit www.imugene.com. Sign up to follow @TeamImugene on Twitter at <http://www.twitter.com/TeamImugene>.

About the Biotech Showcase

Biotech Showcase™, co-produced by EBD Group and Demy-Colton Life Sciences Advisors, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Now in its eighth year, Biotech Showcase 2016 is expected to attract upwards of 2,100 attendees. For further information please visit www.ebdgroup.com/bts/index.php.

For further information please contact:

Imugene:

Leslie Chong, Chief Operating Officer

Tel: +61 458 040 433 (Australia), [leslie.chong \[at\]imugene.com](mailto:leslie.chong@imugene.com)

Paul Hopper, Executive Chairman

Tel: +61 406 671 515 (Australia), [receptogen\[at\]earthlink.net](mailto:receptogen@earthlink.net)

Media:

Rudi Michelson, Monsoon Communications
Tel: +61 3 9620 3333, rudim[at]monsoon.com.au